What is TTRX's stock-based comp?

TTRX (TTRX) reported stock-based comp of $280.83K in Q1 2026.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

TTRX TTRX Stock-Based Comp

Stock-Based Comp at other companies

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

Bausch Health CompaniesBHC

$52M+20.9%

Journey Medical CorporationDERM

$989K-25.2%

PTH

Pelthos Therapeutics Inc.PTHS

$1.91M+293%

Celldex TherapeuticsCLDX

$8.52M-8.5%

Arcutis Biotherapeutics, Inc.ARQT

$10.69M+9.3%

Other financials

Income statement

See full

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

See full

Operating cash flow-$1.6M-448%

Valuation

See full

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

See full

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TTRX's stock-based comp?: TTRX (TTRX) reported stock-based comp of $280.83K in Q1 2026.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.